Quantcast

Latest Carbamates Stories

2014-09-10 16:26:51

Approval based on improved overall survival, delayed time to radiographic progression and an overall positive benefit-risk profile TOKYO and SAN FRANCISCO, Sept. 10, 2014 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc. (Nasdaq: MDVN) announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for the use of XTANDI(®) (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC). This new approved...

2014-07-03 20:20:02

Tokyo, July 3, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received approval from the European Commission of the indication expansion of Halaven (generic name: eribulin mesylate, "eribulin") to contribute to earlier treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should...

2014-07-02 23:03:21

MarketReportsOnline.com adds "Alzheimer’s Disease Patients & Market Worldwide, Future Scenario (2010 – 2015) & Drugs Analysis" report to its research store. Dallas, Texas (PRWEB) July 02, 2014 Alzheimer’s is a complex disease and there is no single “magic bullet” available in the market to prevent or cure it. Though many marketed drugs have been approved for Alzheimer’s disease, it still remains a significant area of unmet medical need. Clinical success has...

2014-06-24 23:13:50

On June 20, the FDA issued a warning that Docetaxel may cause intoxication. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. San Diego, CA (PRWEB) June 24, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on Docetaxel. The FDA issued a safety communication on June 20, warning that Docetaxel may cause patients to experience...

2014-06-11 08:32:20

If You Operate a Business in Tennessee and Indirectly Purchased Skelaxin for Resale Since November 4, 2005, You Could be Affected by a Proposed Class Action Settlement. KNOXVILLE, Tenn., June 11, 2014 /PRNewswire/ -- The following statement is being issued by the Law Offices of Gordon Ball and Hausfeld LLP regarding the Skelaxin Proposed Class Action Settlement. What is this about? Subject to Court Approval, a Settlement has been reached in a class action lawsuit claiming that King...

2014-05-28 23:02:26

The Firm is evaluating Pradaxa bleeding claims on behalf of individuals who allegedly suffered life-threatening episodes of internal hemorrhaging due to their use of Pradaxa. New York, New York (PRWEB) May 28, 2014 As Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/) continue to mount in federal court, Bernstein Liebhard LLP notes that the manufacturer of the blood thinner has acknowledged that a number of serious bleeding events were omitted from the original report on a clinical...

2014-05-27 04:20:05

Indication of Anticancer Agent Halaven for Use in Earlier-Line Treatment of Advanced Breast Cancer Tokyo, May 27, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that its U.K. subsidiary Eisai Europe Limited has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on the indication expansion...

2014-05-23 23:09:43

Ashley Brittain Landers of Schlichter, Bogard & Denton, LLP reports that the FDA has issued a new safety announcement regarding the increased risk of major gastrointestinal (GI) bleeding associated with Pradaxa in comparison to warfarin. The attorneys at Schlichter, Bogard & Denton, LLP are offering free and confidential case reviews to those who allege to have been injured after using Pradaxa. St. Louis, MO (PRWEB) May 23, 2014 On May 13, 2014, the FDA issued a Safety...

2014-05-20 23:14:29

On May 15, the FDA warned that Eszopiclone Containing Sleep Aids (including Lunesta and generics) can cause next-day impairment of driving and other activities that require alertness. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. San Diego, CA (PRWEB) May 20, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on safety alerts...

2014-04-15 12:29:59

PITTSBURGH, April 15, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Eszopiclone Tablets 1 mg, 2 mg and 3 mg, the generic version of Sunovion Pharmaceuticals Inc.'s Lunesta(®). Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of insomnia. Eszopiclone Tablets 1 mg, 2 mg, 3 mg had U.S. sales of approximately $851.8...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related